Companies › KZIA

KAZIA THERAPEUTICS LTD (KZIA)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001075880 · EDGAR filings · Updated 2026-07-28

KAZIA THERAPEUTICS LTD (KZIA) has reported institutional ownership of 0.2%, with 23 institutional managers holding positions valued at $13.0M per the latest 13F reporting period. SEC filings include an active substantial-doubt (going concern) disclosure per the filings.

Filings this week (5)

• 2026-07-28 — Prospectus supplement (424B3) filed
• 2026-07-28 — Prospectus supplement (424B3) filed
• 2026-07-28 — Prospectus supplement (424B3) filed
• 2026-07-28 — Prospectus supplement (424B3) filed
• 2026-07-28 — Foreign issuer report (6-K) filed

Every filing links to the official SEC document. Real-time filing alerts for this company are available inside the app.

Latest updates

• 2026-07-08 — Insider transaction reported (Form 4)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, KAZIA THERAPEUTICS LTD has 23 institutional holders and institutional ownership of 0.2%.

Insider activity

Insiders reported 0 transactions (0 buys, 0 sells) across 1 reporting insiders, with a net reported value of $0.

Data flags from SEC filings

Related companies

Alpha Pro Tech Ltd (APT) · NRX PHARMACEUTICALS INC (NRXP) · ANIXA BIOSCIENCES INC (ANIX) · ATARA BIOTHERAPEUTICS COM NEW (ATRA) · FITLIFE BRANDS INC (FTLF) · Werewolf Therapeutics Inc (HOWL)